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Abstract
Background: Matrix metalloproteinases [MMPs], which degrade the extracellular matrix, play an
important role in the invasion and metastasis of squamous cell carcinomas. One MMP, MMP-13, is
thought to play a central role in MMP activation. The purpose of this study was to investigate MMP-
13 and TIMP-1 expression in squamous cell carcinomas of the head and neck and to relate these
levels of expression to histologic patterns of invasion.
Methods: This study included T1 lesions obtained via biopsy from the larynx, tongue, and skin/
mucosa of 78 patients with head and neck squamous cell carcinomas. The relationship between
expression of MMP-13 and TIMP-1 and the mode of tumor invasion [MI] was evaluated
immunohistochemically, using breast carcinoma tissue as a positive control.
Results:  Increased expression was observed in highly invasive tumors, as reflected by the
significant correlation between the degree of staining for MMP-13 or TIMP-1 and MI grade [p <
0.05]. There was no significant relationship between the degree of staining for MMP-13 or TIMP-1
and patient age, sex, tumor site, or tumor histologic grade. In addition, levels of staining for MMP-
13 did not correlate with levels of staining for TIMP-1.
Conclusion:  The expression of MMP-13 and TIMP-1 appears to play an important role in
determining the invasive capacity of squamous cell carcinomas of the head and neck. Whereas
additional studies are needed to confirm these findings, evaluating expression of these MMPs in
small biopsy samples may be useful in determining the invasive capacity of these tumors at an earlier
stage.
Background
The invasion of surrounding tissues by neoplastic cells is
one of the most important steps in tumor progression.
Proteolytic enzymes such as matrix metalloproteinases
[MMPs] contribute to tumor expansion by degrading
components of the extracellular matrix [ECM]. MMPs are
a 21-member family of zinc-dependent endopeptidases,
which are capable of degrading most ECM components
including collagen, elastin, fibronectin, and gelatin.
Whereas this facilitates processes such as wound healing,
enhanced MMP activity has been observed in a variety of
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pathologic conditions including osteoarthritis, rheuma-
toid arthritis, cardiovascular disease, and neoplasia [1-6].
MMPs can be divided into subgroups, which include col-
lagenases, stromelysins, stromelysins-like MMPs, gelati-
nases, membrane-type MMPs, and others [5]. MMP-13
[collagenase 3] is a member of the collagenase family. It
was first identified in human breast cancer and is active
against a wide variety of ECM components [7]. MMP-13
also plays a central role in the MMP activation cascade,
both activating and being activated by several MMPs [8].
Elevated MMP-13 expression has been found in a number
of different malignancies, and expression has been related
to tumor behavior and patient prognosis [7,9,10].
MMPs can be inactivated by specific tissue inhibitors of
matrix metalloproteinases [TIMPs]. Thus far, four differ-
ent TIMPs [TIMP-1, -2, -3, -4 ] have been identified [11]
and implicated in connective tissue turn-over and remod-
eling. TIMPs inhibit MMPs by binding to them and form-
ing non-covalent complexes [5]. Recent studies have
linked increased MMP expression and decreased TIMP
expression with tumor aggressiveness; however, other
studies have shown overexpression of TIMPs in some
patients with advanced tumors [12,13].
Squamous cell carcinoma [SCC] of the head and neck
region is a major problem. Many studies have shown that
MMPs are expressed in SCCs [5,14,15], with particular
involvement by MMP-2 and MMP -9 [5,13,16]. MMP-13,
which plays a central role in MMP activation, has also
been shown to be highly expressed in head and neck SCCs
[HNSCCs] [5]. As MMPs appear to be essential for tumor
invasion and metastatic spread, characterizing their
expression might help to determine a patient's treatment
or prognosis. Therefore, we investigated the expression of
MMP-13 and TIMP1 in biopsy specimens of HNSCCs to
determine the relationship between the expression of
these proteins and the mode of tumor invasion.
Methods
Patient and tumor characteristics
Between 1998 and 2003, we obtained 78 incisional and
excisional biopsy samples from the primary tumors of 78
patients with invasive SCC who were admitted to the
Head and Neck Surgery and Plastic Surgery Departments.
Fifty-four men and 24 women were included in the study,
and the mean patient age was 64 years [range: 26 to 88
years]. T1 stage tumors from the larynx, tongue, and skin
or mucosa of the face, cheek, lip, nose, and ear were stud-
ied. Table 1 summarizes clinical characteristics of the
patients. None had undergone prior chemotherapy or
radiotherapy. All patients provided informed consent to
participate, and the study protocol was approved by our
institution's ethics committee.
Tumors were histologically graded as well [G1], moder-
ately [G2], or poorly [G3] differentiated [Table 1]. The
mode of tumor invasion [MI] was graded as follows: grade
1, well-defined border; grade 2, less-marked border; grade
3, groups of cells with no distinct border; grade 4, diffuse
invasion [a, cordlike; b, widespread] [Table 1].
Immunohistochemical procedures
The most representative block of tumor tissue was chosen
in each case, and 5-µm sections were obtained and
mounted on poly-L-lysine-coated slides for immunohis-
tochemical staining. A standard streptavidin-biotin
immunoperoxidase method was used for immunostain-
ing with MMP-13 [7 ml, MS-825-R7, Ready-to-use, Neo-
markers, USA] and TIMP-1 [7 ml, MS-608-R7, Ready-to-
use, Neomarkers, USA] antibodies. The tissue sections
were deparaffinized in xylene, rehydrated in an alcohol
series, and immersed in distilled water. The sections were
then boiled in a citrate buffer solution [10 mmol/L, pH=
6.0] in a microwave oven X3 for 10 minutes for antigen
retrieval of both the MMP-13 and TIMP-1 antibodies.
Endogenous peroxidase activity was blocked by exposing
sections to a 0.3% solution of hydrogen peroxidase in
phosphate-buffered saline [PBS] for 10 minutes at room
temperature. After the sections had been rinsed with TRIS
buffer, primary antibodies were applied for 60 minutes at
room temperature followed by TRIS buffer. Linking anti-
body and streptavidin peroxidase complex were then
added consecutively for 10 minutes at room temperature,
and sections were washed again in TRIS buffer. After
applying AEC chromogen, the sections were washed in
deionized water, counterstained and mounted. Breast car-
cinoma tissue (which showed positive staining) was used
Table 1: Clinicopathologic features
Characteristic Number of cases 
Age
< 60 years 27
> 60 years 51
Sex
Male 54
Female 24
Tumor site
Larynx 26
Tongue 8
Skin and mucosa 44
Histologic grade
Differentiated (G1) 39
Poorly differentiated (G2, G3) 39
Mode of tumor invasion
Well defined (1 + 2) 18
No distinct border (3) 43
Diffuse invasion (4a + 4b) 17BMC Cancer 2004, 4:42 http://www.biomedcentral.com/1471-2407/4/42
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as positive control during the evaluation of MMP-13 and
TIMP-1 immunostaining.
Evaluation/scoring of the staining
One pathologist [NC] evaluated the stained slides associ-
ated with each case. The degree of staining for MMP-13
and TIMP-1 was scored as follows: 0, no staining of the
tumor or stromal cells; 1+, weak [< 50%] positive staining
of the tumor cells and/or weak staining of stromal cells;
2+, moderate [> 50%] positive staining of the tumor cells
and/or moderate staining of stromal cells; 3+, extensive
staining of the tumor cells and/or strong staining of stro-
mal cells [Figs. 1,2] [12]. No normal epithelial cells were
stained [Fig. 3].
Follow-up
If necessary, surgery or radiotherapy was performed after
the diagnosis. All patients were followed-up postopera-
tively for a mean interval of 20 months [range: 7 to 36
months]. During this period, 2 of 78 [2.6%] patients died
from their tumors [one in larynx, one in tongue], and 1
patient died of an unrelated cause. Seventy-five of 78
[96.2%] patients were free of disease at the end of the fol-
low-up period.
Statistical analysis
The chi-square test was used for statistical analysis. Data
were analyzed using SPSS for Windows 10,0. A p level
<0.05 was considered to be statistically significant.
Results
Although expression of cytoplasmic MMP-13 was prima-
rily detected in tumor cells, it also was seen in stromal
cells. MMP-13 expression was evident in tissue from 44
Moderate MMP-13 staining of the tumor cells in MI grade 2 SCC (anti-MMP-13, original magnification, × 100) Figure 1
Moderate MMP-13 staining of the tumor cells in MI grade 2 SCC (anti-MMP-13, original magnification, × 100)BMC Cancer 2004, 4:42 http://www.biomedcentral.com/1471-2407/4/42
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[56.4%] of the 78 patients. High levels of MMP-13 were
noted in highly invasive tumors. There was no difference
in the amount of staining between tumor centers or mar-
gins. Significant TIMP-1 expression was detected in tissue
from 42 [53.8%] patients. Prominent labeling was con-
fined to the stroma surrounding the tumor cells.
Table 2 shows the relationship between MMP-13 expres-
sion and MI in the 78 biopsy specimens. Increased expres-
sion of MMP-13 was observed in highly invasive tumors
[MI grades 4a and b]. The relationship between MMP-13
expression and MI grade was statistically significant [p <
0.05].
Table 3 summarizes the relationship between TIMP-1
expression and MI in the 78 biopsy specimens. Increased
expression of TIMP-1 was observed in highly invasive
tumors. The relationship between TIMP-1 expression and
MI grade was statistically significant [p < 0.05].
There was no statistically significant relationship between
the degree of staining for MMP-13 or TIMP-1 and patient
age, sex, tumor site, or histologic grade. Also, the degree of
staining for MMP-13 did not significantly correlate with
the degree of staining for TIMP-1.
Moderate TIMP-1 staining of the stromal cells in MI grade 3 SCC (anti-TIMP-1, original magnification, × 200) Figure 2
Moderate TIMP-1 staining of the stromal cells in MI grade 3 SCC (anti-TIMP-1, original magnification, × 200)BMC Cancer 2004, 4:42 http://www.biomedcentral.com/1471-2407/4/42
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Normal epithelial cells at the top were not stained with MMP-13 (anti-MMP-13, original magnification, × 200) Figure 3
Normal epithelial cells at the top were not stained with MMP-13 (anti-MMP-13, original magnification, × 200)BMC Cancer 2004, 4:42 http://www.biomedcentral.com/1471-2407/4/42
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Discussion
As tumor invasion and metastasis affect a patient's prog-
nosis, it is important to predict the invasive potential of
tumors such as SCCs at an early stage. Several steps are
involved in the invasion and metastasis of malignant cells
including the attachment of cells to the ECM, the break-
down of matrix components, cell detachment, and migra-
tion of cells through the degraded matrix. This complex
process requires several proteases, and the local balance
between these proteases and protease inhibitors appears
to be crucial. The MMPs represent one family of degrading
proteases, which are expressed in various tumors. Many
studies have shown that MMPs, especially MMP-2, -3, -9,
are expressed in SCCs [5,12,16-18]. In the present study,
we characterized the expression of one MMP–MMP-13,
which plays a key role in the MMP activation cascade–and
one inhibitor of MMPs, TIMP-1, in HNSCCs. Our finding
that expression of both proteins was upregulated in mark-
edly invasive tumors is consistent with prior reports and
may have important therapeutic and prognostic
implications.
The expression of several MMPs has been investigated in
SCCs including MMP-9 and MMP-13. MMP-9 expression
was found to correlate the most strongly with advanced
pathological stages, and patients with HNSCCs also may
have elevated serum concentration of MMP-9 [17,19].
Furthermore, expression of some MMPs such as MMP-9
appears to vary not only between the primary tumor and
sites of lymph node metastasis, but also between the early
and late stages of lymph node metastasis [16].
MMP-13 is a member of the collagenase family, which
degrades fibrillar collagens of types I, II, III, IV, X, and XIV,
tenascin, fibronectin, aggrecan, versican, and fibrillin-I. It
is now accepted that MMP-13 plays a key role in the MMP
activation cascade, both activating and being activated by
several MMPs [MT1-MMP, MMP-2, MMP-3] [8,11]. MMP-
13 expression is also susceptible to stimulation by several
cytokines and growth factors such as TNF-α and TGF-β
[11,15]. Elevated MMP-13 expression has been docu-
mented in numerous malignancies [e.g., breast carci-
noma, colorectal cancer, vulvar SCC, skin SCC, HNSC,
BCC (in focal areas of keratinized cells)] and associated
with tumor behavior and patient prognosis [1,7-10,20].
Table 2: Relationship between level of MMP-13 expression and MI
MMP-13 staining
Grade of tumor invasion Negative/weak (0 + 1) Moderate/ extensive (2 + 3) Total
1 (1 + 2) 15 (83.3%) 3 (16.7%) 18
2 (3) 14 (32.6%) 29 (67.4%) 43
3 (4a + 4b) 5 (29.4%) 12 (70.6%) 17
Total 34 44 78
MI: mode of tumor invasion (expressed as grade). p values: 0.001
Table 3: Relationship between level of TIMP-1 expression and MI
TIMP-1 staining
Grade of tumor invasion Negative/weak (0 + 1) Moderate/ extensive (2 + 3) Total
1 (1 + 2) 13 (72.2%) 5 (27.8%) 18
2 (3) 16 (37.2%) 27 (62.8%) 43
3 (4a + 4b) 7 (41.2%) 10 (58.8%) 17
Total 36 42 78
MI: mode of tumor invasion (expressed as grade). p values: 0.03BMC Cancer 2004, 4:42 http://www.biomedcentral.com/1471-2407/4/42
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Both small and large tumors appear to express MMP-13,
with expression being the most prevalent in undifferenti-
ated tumors [11].
MMP-13 expression has also been observed in trans-
formed, but not primary, human epidermal keratinocytes
[11,15]. Although MMP-1, -2, -3 have been detected in
actinic keratosis [12,21], premalignant and benign
tumors were mostly negative for MMP-13 in one study
[20]. It is thought that MMP-13, alone, can markedly
enhance the invasive capacity of malignant cells [22]. In
transformed keratinocytes, p 53 plays an important role in
suppressing MMP-13 expression [23]. Whereas some
investigators have not found a significant relationship
between MMP-13 expression and HNSCC behavior [17],
we found significant MMP-13 expression in highly
invasive tumors; this finding suggests that MMP-13 likely
plays a role in regulating tumor invasion. In regard to
location, cellular events at the tumor-stromal interface are
thought to be more closely related to metastatic potential
than events at the tumor's center [17,24]. Others have
reported that MMP-13 is not only expressed by tumor
cells in the invading periphery of most SCCs but also by
stromal cells in a subset of tumors [15]. In the present
study, we found no difference in levels of MMP-13 expres-
sion between tumor centers or margins.
TIMP-1 is another protein that has been implicated in
tumor growth. TIMP-1 mRNA has been detected in well-
differentiated cancer cells, proliferated keratinocytes, and
endothelial cells [2,14], and TIMP-1 overexpression has
been observed in almost every case of HNSCC [24].
Whereas some investigators have reported that increased
expression of TIMP-1 and TIMP-2 correlates with less
aggressive tumors, others have reported the opposite find-
ing [12,13]. In the present study, TIMP-1 expression was
significantly increased in markedly invasive tumors, sug-
gesting that TIMP-1 also plays a role in regulating tumor
invasiveness.
In some studies, no association between MMP-13 and
TIMP-1 expression and any clinicopathological variables
was found, or TIMP expression did not correlate with
tumor growth [13,17]. Our results are not compatible
with these studies. However, we did fail to identify any
statistically significant relationship between the degree of
staining for MMP-13 or TIMP-1 and the patient's age, sex,
tumor site, or tumor histologic grade. Also, there was no
statistically significant correlation between the degree of
staining for MMP-13 and TIMP-1. This suggests that the
balance between MMP and TIMP expression may not be
as important to tumor invasion as their overexpression;
that is, MMP and TIMP may play important separate roles
in tumor invasion in which they act via different
mechanisms.
Because of the relatively short follow-up interval, we are
unable to demonstrate whether MMP-13 and TIMP-1
expression is related to long-term survival. However, 75 of
our 78 patients were free of disease after a mean follow-up
interval of 20 months. As poor outcomes are the result of
local recurrences and distant metastasis, factors that reflect
the invasive and metastatic potential of SCCs, such as
MMPs, could be helpful in predicting patient prognosis.
Thus, further investigation of MMPs may not only clarify
their role in tumor invasion but also may facilitate the
development of new therapeutic approaches.
Conclusion
The results of this study suggest that MMP-13, which plays
a central role in MMP activation, and the MMP inhibitor,
TIMP-1, help regulate the invasiveness of HNSCCs.
Although other methods [e.g., Western blots] are needed
to confirm these findings, examination of MMP-13 and
TIMP-1 expression in small biopsy samples might be use-
ful in determining the invasive capacity of these tumors at
an earlier stage.
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